For over 10 years, Sandostatin® LAR Depot (octreotide acetate for injectable suspension) has demonstrated unparalleled evidence in acromegaly and has been a trusted medical therapy. In addition, Sandostatin® LAR Depot is the only medical therapy proven to reduce tumor size in patients with acromegaly. Two separate clinical studies have demonstrated that Sandostatin® LAR Depot not only helps relieve the symptoms of acromegaly, but it also shrinks tumors.
- Sandostatin® LAR Depot is a type of medical treatment for acromegaly called a somatostatin analogue
- Sandostatin® LAR Depot works by reducing both growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels
- In addition to being the number one prescribed somatostatin analogue in the world, Sandostatin® LAR Depot is the only medical therapy for acromegaly proven to shrink tumors
Control you can trust
Sandostatin® offers you:
- 20 years of unparalleled evidence, established through*1,3
- Over 6000 published articles† 2,3
- Over 600 clinical trials†2,3
*Combined use of immediate release Sandostatin® Injection and Sandostatin® LAR Depot for all approved indications.
†Includes both ongoing and complete trials for all approved indications.
Remember to always report any symptoms as accurately as possible and discuss these with your doctor. This will ensure that you get the best dosage for your treatment.
Sandostatin® LAR Depot (octreotide acetate for injectable suspension) is indicated for long-term maintenance therapy in acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option. The goal of treatment in acromegaly is to reduce GH and IGF-1 levels to normal.
Important Safety Information:
As with immediate release Sandostatin® Injection, the most frequently reported drug-related adverse events were biliary disorders (52%), gastrointestinal disorders (7% to 36%), and injection-site pain (2% to 11%). Hypoglycemia (2%), hyperglycemia (15%), and hypothyroidism (2%) have been reported. While not measured in acromegalic patients receiving Sandostatin® LAR Depot, ECG changes have been reported in patients receiving immediate release Sandostatin® Injection; the degree to which these abnormalities are related to octreotide acetate is not clear, as many acromegalics have cardiovascular disease. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
